Search company, investor...


Founded Year



Grant | Alive

Total Raised


Last Raised

$150K | 13 yrs ago

About Parsortix

Parsortix technology is a physical separation device that enables the user to capture particles of different types suspended in fluid media using a patented separation process. The device design can be 'tuned' to capture particles of different sizes and has a wide range of potential applications in medical devices and diagnostics. The device has been successfully shown to be capable of separating fetal cells from whole peripheral maternal blood, and to be capable of capturing and separating different kinds of white blood cells from whole blood.

Headquarters Location

3711 Market Street University City Science Center, 8th Floor

Philadelphia, Pennsylvania, 19104,

United States


Missing: Parsortix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Parsortix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Parsortix Patents

Parsortix has filed 6 patents.

patents chart

Application Date

Grant Date


Related Topics




Nanotechnology, Molecular biology, Cell biology, Biotechnology, Clusters of differentiation


Application Date


Grant Date



Related Topics

Nanotechnology, Molecular biology, Cell biology, Biotechnology, Clusters of differentiation



Latest Parsortix News

Dr. Lang on the Potential Applications for the Parsortix® PC1 System in Breast Cancer

Feb 2, 2023

Feb 2, 2023 Julie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer. Julie Lang, MD, chief of Breast Surgery, co-leader of the Breast Cancer Program, General Surgery, the Cleveland Clinic Main Campus, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer. The Parsortix PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood from patients with metastatic breast cancer. In May 2022, the FDA granted class II clearance for Parsortix as a diagnostic for metastatic breast cancer, making it the first device approved for the use of detecting cancer by harvesting cells from a patient blood sample. The approval was based on findings from a prospective clinical trial (NCT03427450) conducted at The University of Texas MD Anderson Cancer Center, the University of Southern California, the Northwestern Medical Center, and the University of Rochester, which evaluated blood samples taken from patients with breast cancer and healthy female volunteers with no history of cancer. Findings presented at the 2022 San Antonio Breast Cancer Symposium showed that harvested cells can be evaluated using standard orthogonal methodologies, such as gene expression and fluorescence in situ hybridization, to identify and characterize CTCs. Although investigators were excited about the trial’s findings and the FDA approval, additional studies could include better cytology methods so that a higher proportion of CTCs adhere to the cytology slides used in the device, Lang notes. Based on cell line proof-of-principle studies done in parallel to the clinical trial, 37% to 51% of the CTCs were harvested by Parsortix, meaning the test could have increased sensitivity with more refined cytology methods, Lang says. Lang explains that sequencing studies to detect mutations could also be performed, and other studies could include single-cell sequencing to examine tumor biology and better understand resistance in metastatic breast cancer cells. Individual hospitals will need to decide how to apply Parsortix and what subsequent studies may be beneficial in their patient populations, Lang concludes. Related Videos

Parsortix Frequently Asked Questions (FAQ)

  • When was Parsortix founded?

    Parsortix was founded in 2006.

  • Where is Parsortix's headquarters?

    Parsortix's headquarters is located at 3711 Market Street, Philadelphia.

  • What is Parsortix's latest funding round?

    Parsortix's latest funding round is Grant.

  • How much did Parsortix raise?

    Parsortix raised a total of $150K.

  • Who are the investors of Parsortix?

    Investors of Parsortix include National Science Foundation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.